Epstein Secrets

Efficacy Standards For Vaccine. The Washington Post (10/22, McGinley, Johnson, 14.2M) reports that vaccine experts on Thursday "rigorously debated the Food and Drug Administration's planned standards for clearing a coronavirus vaccine quickly for broad use, discussing what level of evidence would be sufficient to establish safe

ard, not the relatively low bar used this year for emergency use authorization for treatments." Calling the meeting "an usual step," the AE (10/22, Neergaard, Perrone) reports Dr. Marion Gruber, director of FDA's vaccine research office, told the advisers that public scrutiny "is critical to build trust

0/22/covid-vaccine-safety-effectiveness- guidelines/> (10/22, McGinley, Johnson, 14.2M) reports that vaccine experts on Thursday "rigorously debated the Food and Drug Administration's planned standards for clearing a coronavirus vaccine quickly for broad use, discussing what level of evidence would be sufficient to establish safet

for treatments." Calling the meeting "an usual step," the AP <https://apnews.corn/article/virus-outbreak- e49203f5c55ba593ca587a56d0116b97> (10/22, Neergaard, Perrone) reports Dr. Marion Gruber, director of FDA's vaccine research office, told the advisers that public scrutiny "is critical to build trust a

Efficacy Standards For Vaccine. The Washington Post (10/22, McGinley, Johnson, 14.2M) reports that vaccine experts on Thursday "rigorously debated the Food and Drug Administration's planned standards for clearing a coronavirus vaccine quickly for broad use, discussing what level of evidence would be sufficient to establish safe

ard, not the relatively low bar used this year for emergency use authorization for treatments." Calling the meeting "an usual step," the AP (10/22, Neergaard, Perrone) reports Dr. Marion Gruber, director of FDA's vaccine research office, told the advisers that public scrutiny "is critical to build trust